How we turn opacity into a score.
Every provider is measured against the same published rubric. The score is the score — it cannot be bought, lobbied, or upgraded by advertising with us.
The six pillars
Weightings reflect what actually protects a patient: who is prescribing, where the medication is compounded, and whether the price you're quoted is the price you pay across the full dose ladder.
- Clinical Protocol & Named Medical Director20 pts
A verifiable MD/DO with state licensure, individualized prescribing over standing orders, and a documented clinical-oversight structure.
- Pharmacy Traceability & Certificate of Analysis20 pts
Named 503A/503B pharmacy partners disclosed in writing, with USP <71> sterility, USP <85> endotoxin, and HPLC potency CoA available on request.
- Real-World Cohort Outcomes & Adverse-Event Disclosure20 pts
Published cohort outcomes, transparent adverse-event reporting, and documented discontinuation rates rather than marketing testimonials.
- All-Inclusive Flat Pricing15 pts
A flat monthly rate across the full titration ladder (2.5 → 15 mg for tirzepatide) with no dose-based upcharges and no hidden fees.
- Lab Integration & Longitudinal Follow-Up15 pts
Quest/Labcorp integration and scheduled clinician check-ins at 4, 12, 26, and 52 weeks — not a one-time intake form.
- Regulatory Clarity10 pts
Semaglutide/tirzepatide base only (no FDA-flagged salt forms), an explicitly stated 503A vs 503B pathway, and active FDA-shortage-status tracking.
Rankings are non-payable.
Rankings are editorial and non-payable. No provider can pay for placement, a higher score, or favorable coverage. GLP Review is affiliate-supported; affiliate relationships never influence scores, which are determined solely by the published v3.0 six-pillar rubric.
When we're wrong, we say so.
Material errors are corrected promptly and logged publicly with the date and nature of the change. Email [email protected] to request a correction.
Contact: [email protected]
What we score against, and what we don't.
Pillar 1 (Clinical Protocol & Named Medical Director) is verified against state medical-board licensure lookups for the named clinician(s), and against the provider's published clinical protocol where one exists.
Pillar 2 (Pharmacy Traceability & Certificate of Analysis) is verified against the provider's written pharmacy-partner disclosure, the named pharmacy's state pharmacy-board licensure record, and — where requested — a sample certificate of analysis covering sterility (USP <71>), bacterial endotoxin (USP <85>), and potency (HPLC) for a recent batch.
Pillar 3 (Real-World Outcomes & Adverse-Event Disclosure) is verified against any publicly-available cohort outcomes the provider has published, and against the provider's adverse-event response protocol. In the absence of published data, we infer from clinical-protocol quality and direct review.
Pillar 4 (All-Inclusive Flat Pricing) is verified against the provider's published pricing schedule across the full dose ladder, and — where pricing is described as flat — against a documented test-quote at the dose we expect to be the maintenance dose.
Pillar 5 (Lab Integration & Longitudinal Follow-up) is verified against the provider's documented lab cadence and partner-lab integration (Quest, LabCorp).
Pillar 6 (Regulatory Clarity) is verified against the provider's public representation of compounded-product status, 503A vs 503B pathway description, and current FDA shortage-status tracking.
We do not score against unverifiable marketing claims, anonymous reviews, or social-media volume.
When the ranking changes.
The main provider ranking is reviewed quarterly. Material changes — a provider changing its pricing model, adding or losing a named pharmacy partner, or a meaningful regulatory event — trigger an out-of-cycle re-score for the affected provider.
Pricing fields (priceLabel and priceMonthly) are verified at least monthly against the provider's public quote. The Corrections log records any instances where a published price drifted between scheduled refreshes.
The rubric itself (the six-pillar weighting and per-pillar threshold) is reviewed annually. The current rubric is v3.0, in effect since February 2026.
v1 → v3 change log.
- v1.0 · Initial publication
Five pillars, equal weighting at 20 points each, no per-pillar pass threshold. Clinical Protocol, Pharmacy, Pricing, Labs, and Regulatory. Outcomes was not yet a separate pillar; clinical-quality observations were folded into Clinical Protocol.
- v2.0 · Six pillars + per-pillar threshold
Added a sixth pillar (Outcomes & Adverse-Event Disclosure) at 20 points, splitting it from Clinical Protocol. Total points raised from 100 to 100 with redistribution. Added a 60% per-pillar pass threshold for a transparency-compliant designation.
- v3.0 · Raised threshold + sub-criteria
Raised the per-pillar pass threshold from 60% to 70%, materially tightening the transparency-compliant designation. Added explicit sub-criteria under Pharmacy Traceability for documented cold-chain shipping practice and certificate-of- analysis on patient request. In effect since February 12, 2026.
If you're a provider, how to request a re-review.
Providers may request a re-review under the published rubric at any time. Effective re-review requests include: the URL of the existing review, the specific pillar(s) being addressed, the documentation supporting the re-score (clinical protocol, pharmacy disclosure, pricing schedule), and a contact at the provider for follow-up questions.
Re-reviews are editorial and non-payable. We do not accept payment in any form for re-scoring, expedited review, or any other adjustment.
Send re-review requests to [email protected].